Literature DB >> 28626521

Identification and Characterization of JAK2 Pseudokinase Domain Small Molecule Binders.

David E Puleo1, Kaury Kucera1, Henrik M Hammarén2, Daniela Ungureanu2, Ana S Newton1, Olli Silvennoinen2, William L Jorgensen1, Joseph Schlessinger1.   

Abstract

Janus kinases (JAKs) regulate hematopoiesis via the cytokine-mediated JAK-STAT signaling pathway. JAKs contain tandem C-terminal pseudokinase (JH2) and tyrosine kinase (JH1) domains. The JAK2 pseudokinase domain adopts a protein kinase fold and, despite its pseudokinase designation, binds ATP with micromolar affinity. Recent evidence shows that displacing ATP from the JAK2 JH2 domain alters the hyperactivation state of the oncogenic JAK2 V617F protein while sparing the wild type JAK2 protein. In this study, small molecule binders of JAK2 JH2 were identified via an in vitro screen. Top hits were characterized using biophysical and structural approaches. Development of pseudokinase-selective compounds may offer novel pharmacological opportunities for treating cancers driven by JAK2 V617F and other oncogenic JAK mutants.

Entities:  

Keywords:  JAK2; JH2; MPN; Pseudokinase; Small molecule

Year:  2017        PMID: 28626521      PMCID: PMC5467198          DOI: 10.1021/acsmedchemlett.7b00153

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  19 in total

1.  Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain.

Authors:  Pipsa Saharinen; Mauno Vihinen; Olli Silvennoinen
Journal:  Mol Biol Cell       Date:  2003-04       Impact factor: 4.138

2.  Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).

Authors:  Xiaoshan Min; Daniela Ungureanu; Sarah Maxwell; Henrik Hammarén; Steve Thibault; Ellin-Kristina Hillert; Merrill Ayres; Brad Greenfield; John Eksterowicz; Chris Gabel; Nigel Walker; Olli Silvennoinen; Zhulun Wang
Journal:  J Biol Chem       Date:  2015-09-10       Impact factor: 5.157

3.  A quantitative analysis of kinase inhibitor selectivity.

Authors:  Mazen W Karaman; Sanna Herrgard; Daniel K Treiber; Paul Gallant; Corey E Atteridge; Brian T Campbell; Katrina W Chan; Pietro Ciceri; Mindy I Davis; Philip T Edeen; Raffaella Faraoni; Mark Floyd; Jeremy P Hunt; Daniel J Lockhart; Zdravko V Milanov; Michael J Morrison; Gabriel Pallares; Hitesh K Patel; Stephanie Pritchard; Lisa M Wodicka; Patrick P Zarrinkar
Journal:  Nat Biotechnol       Date:  2008-01       Impact factor: 54.908

4.  ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.

Authors:  Henrik M Hammarén; Daniela Ungureanu; Jean Grisouard; Radek C Skoda; Stevan R Hubbard; Olli Silvennoinen
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-30       Impact factor: 11.205

5.  Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition.

Authors:  Patrick J Lupardus; Mark Ultsch; Heidi Wallweber; Pawan Bir Kohli; Adam R Johnson; Charles Eigenbrot
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-19       Impact factor: 11.205

Review 6.  The JAK-STAT pathway: impact on human disease and therapeutic intervention.

Authors:  John J O'Shea; Daniella M Schwartz; Alejandro V Villarino; Massimo Gadina; Iain B McInnes; Arian Laurence
Journal:  Annu Rev Med       Date:  2015       Impact factor: 13.739

7.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

8.  JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors.

Authors:  Alexandra Dusa; Céline Mouton; Christian Pecquet; Murielle Herman; Stefan N Constantinescu
Journal:  PLoS One       Date:  2010-06-16       Impact factor: 3.240

9.  Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase.

Authors:  Yibing Shan; Kavitha Gnanasambandan; Daniela Ungureanu; Eric T Kim; Henrik Hammarén; Kazuo Yamashita; Olli Silvennoinen; David E Shaw; Stevan R Hubbard
Journal:  Nat Struct Mol Biol       Date:  2014-06-11       Impact factor: 15.369

10.  Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F.

Authors:  Rajintha M Bandaranayake; Daniela Ungureanu; Yibing Shan; David E Shaw; Olli Silvennoinen; Stevan R Hubbard
Journal:  Nat Struct Mol Biol       Date:  2012-07-22       Impact factor: 15.369

View more
  10 in total

1.  Selective Janus Kinase 2 (JAK2) Pseudokinase Ligands with a Diaminotriazole Core.

Authors:  Maria-Elena Liosi; Stefan G Krimmer; Ana S Newton; Thomas K Dawson; David E Puleo; Kara J Cutrona; Yoshihisa Suzuki; Joseph Schlessinger; William L Jorgensen
Journal:  J Med Chem       Date:  2020-05-08       Impact factor: 7.446

Review 2.  Janus kinases to jakinibs: from basic insights to clinical practice.

Authors:  Massimo Gadina; Mimi T Le; Daniella M Schwartz; Olli Silvennoinen; Shingo Nakayamada; Kunihiro Yamaoka; John J O'Shea
Journal:  Rheumatology (Oxford)       Date:  2019-02-01       Impact factor: 7.580

3.  Metadynamics as a Postprocessing Method for Virtual Screening with Application to the Pseudokinase Domain of JAK2.

Authors:  Kara J Cutrona; Ana S Newton; Stefan G Krimmer; Julian Tirado-Rives; William L Jorgensen
Journal:  J Chem Inf Model       Date:  2020-05-27       Impact factor: 4.956

4.  Role of water in the determination of protonation states of titratable residues.

Authors:  Syeda Rehana Zia
Journal:  J Mol Model       Date:  2021-01-31       Impact factor: 1.810

5.  Analyzing Resistance to Design Selective Chemical Inhibitors for AAA Proteins.

Authors:  Rudolf Pisa; Tommaso Cupido; Jonathan B Steinman; Natalie H Jones; Tarun M Kapoor
Journal:  Cell Chem Biol       Date:  2019-06-27       Impact factor: 8.116

6.  Indoloxytriazines as binding molecules for the JAK2 JH2 pseudokinase domain and its V617F variant.

Authors:  Ana S Newton; Maria-Elena Liosi; Sean P Henry; Luca Deiana; John C Faver; Stefan G Krimmer; David E Puleo; Joseph Schlessinger; William L Jorgensen
Journal:  Tetrahedron Lett       Date:  2021-07-02       Impact factor: 2.032

7.  Conversion of a False Virtual Screen Hit into Selective JAK2 JH2 Domain Binders Using Convergent Design Strategies.

Authors:  Sean P Henry; Maria-Elena Liosi; Joseph A Ippolito; Kara J Cutrona; Stefan G Krimmer; Ana S Newton; Joseph Schlessinger; William L Jorgensen
Journal:  ACS Med Chem Lett       Date:  2022-04-21       Impact factor: 4.632

8.  Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways.

Authors:  Yu Zhou; Xin Li; Ru Shen; Xiangzhu Wang; Fan Zhang; Suxing Liu; Di Li; Jian Liu; Puhui Li; Yinfa Yan; Ping Dong; Zhigao Zhang; Heping Wu; Linghang Zhuang; Rasheduzzaman Chowdhury; Matthew Miller; Mena Issa; Yuchang Mao; Hongli Chen; Jun Feng; Jing Li; Chang Bai; Feng He; Weikang Tao
Journal:  Front Immunol       Date:  2022-05-20       Impact factor: 8.786

9.  Covalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 (TRIB2) pseudokinase in cancer cells.

Authors:  Daniel M Foulkes; Dominic P Byrne; Wayland Yeung; Safal Shrestha; Fiona P Bailey; Samantha Ferries; Claire E Eyers; Karen Keeshan; Carrow Wells; David H Drewry; William J Zuercher; Natarajan Kannan; Patrick A Eyers
Journal:  Sci Signal       Date:  2018-09-25       Impact factor: 8.192

Review 10.  JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.

Authors:  William Vainchenker; Emilie Leroy; Laure Gilles; Caroline Marty; Isabelle Plo; Stefan N Constantinescu
Journal:  F1000Res       Date:  2018-01-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.